Data on Electronic Sampling, Online Promotion, Tech-Enabled Reps, Customer Service, and iPads

Manhattan ResearchPharmaceutical and healthcare market research company Manhattan Research releases the tenth version of ePharma Physician®, its study focused on physicians connecting with pharmaceutical and biotech companies through the Internet, tech-enabled reps, and online promotion. ePharma Physicians comprise 88% of the U.S. physician population in 2010, up from 64% in 2006.

Manhattan Research broadened the topical focus of ePharma Physician® this year to analyze the growing number of touch points in the pharma-physician relationship. Electronic sampling, live video detailing, and physician use of mobile devices, including iPads, are a few of the topics with new and exciting data. Pharmaceutical and biotech companies, agencies, and medical content providers use the data to inform decision making when leveraging digital channels to interact with physicians. The study can be segmented to derive statistically relevant insights across more than 25 specialties.

Key topics:

  • Channel Mix: Online and offline sources used for pharma product information; display and search engine advertising; medical journals; specialty and professional medical websites; influence on prescribing behavior
  • Mobile: Interest in pharma activities on mobile devices; iPad ownership and purchase intent; professional activities conducted on the iPad
  • Rep Relationship and Tech Detailing: Rep use/attitudes, including reps using Tablet PC or iPad; desired rep services
  • Online Promotion: Types of e-detailing and non-personal promotion (NPP) used, number of times used, program duration; live video detailing; KOL-led speaker programs; HCP portals/microsites; online promotion attitudes, influence, and barriers; preferences for obtaining product information; ranking of e-detailing and video detailing programs by company (use and satisfaction)
  • Online Pharmaceutical Properties: Pharma product, corporate, service portal, and unbranded websites
  • Customer Service: Customer service portal use and features of interest; live online speaker events from pharma companies; preferences for communicating with reps and MSLs; interest in customer service through email, click-to-chat, click-to-call, video chat, and phone; reasons for registering for a service portal
  • Electronic Sampling: Use and frequency; preferences for obtaining samples

Complimentary White Paper
To access a complimentary white paper from ePharma Physician® v10.0, please visit http://www.manhattanresearch.com/research/white-papers/online-communication-physicians-pharma.aspx

About ePharma Physician®
ePharma Physician® v10.0 was conducted via online survey in Q2 2010 among 1,713 U.S. physicians who have looked online for pharmaceutical information, visited a pharmaceutical or biotech product or corporate website, or participated in an e-detailing program from a pharmaceutical or biotech company in the past 12 months.

For additional information, please visit http://www.manhattanresearch.com/epp

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a global pharmaceutical and healthcare market research and strategic advisory firm and conducts annual research studies covering eHealth trends among physicians and consumers. Broad consumer and physician research is complemented by analysis for over 100 consumer therapeutic segments and physician specialist segments. For more information, please visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.decisionresourcesinc.com.

Most Popular Now

Pfizer and Lilly announce top-line results from lo…

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg. The objective of the stu...

Bristol-Myers Squibb reports first quarter financi…

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2019 which were highlighted by strong demand for Opdivo (nivolumab) and Eliquis (a...

Walnuts may help lower blood pressure for those at…

When combined with a diet low in saturated fats, eating walnuts may help lower blood pressure in people at risk for cardiovascular disease, according to a new Penn State ...

Amgen ignites a social fitness movement to support…

Amgen (NASDAQ:AMGN) launched the Breakaway Challenge initiative, a national social fitness program to motivate individuals to take action in their health and to support t...

Comprehensive tumor profiling promises new therape…

The WINTHER trial, NCT01856296, led by investigators from Vall d'Hebron Institute of Oncology - VHIO (Spain), Chaim Sheba Medical Center (Israel) (Raanan Berger), Gustave...

AstraZeneca starts artificial intelligence collabo…

AstraZeneca and BenevolentAI today began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treat...

Possible link between autism and antidepressants u…

An international team led by Duke-NUS Medical School has found a potential link between autistic-like behaviour in adult mice and exposure to a common antidepressant in t...

Chemotherapy or not?

Case Western Reserve University researchers and partners, including a collaborator at Cleveland Clinic, are pushing the boundaries of how "smart" diagnostic-imaging machi...

Researchers define Alzheimer's-like brain disorder

A brain disorder that mimics symptoms of Alzheimer's disease has been defined with recommended diagnostic criteria and guidelines for advancing future research on the con...

Drugs to prevent stroke and dementia show promise …

Treatments that prevent recurrence of types of stroke and dementia caused by damage to small blood vessels in the brain have moved a step closer, following a small study...

Amgen and Syapse enter precision medicine collabor…

Amgen (NASDAQ:AMGN), a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, announced a precisio...

Personalizing precision medicine with combination …

Precision oncology often relies on treating patients with a single, molecularly matched therapy that targets one mutation in their tumor. In a report, published online in...